source
- Thiel-backed Lindus Therapeutics sells CRO division and shifts focus to acquiring drug assetsLindus Therapeutics, a transatlantic startup backed by Peter Thiel, announced the sale of its contract research organization (CRO) arm. The company, previously positioning itself as an “anti‑CRO,”…
- Ultragenyx’s Angelman therapy fails Phase 3, stock drops over 43% and company announces strategic reviewUltragenyx reported that its investigational Angelman syndrome drug apazunersen did not meet the primary cognitive endpoints in a Phase 3 trial. The lack of efficacy means the therapy will not prov…